With two recently failed late-stage cancer candidates, CTI BioPharma Corp. is hoping that the third time is the charm -- the troubled biotech inked a global commercialization agreement with Baxter International Inc. that it believes is a validation of the direction it’s taking.
CTI announced Nov. 15 that it has fulfilled its promise to investors to find a partner for its Phase III...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?